Kardigan completes enrollment in two late-stage cardiovascular trials, reports Q3 2026 resultsNov 12Quarterly updateataciguatdanicamtiv
Kardigan advances three late-stage cardiovascular trials, reports $660.7M cashAug 11Quarterly updatedanicamtivKardigan
Ionis posts Q2 2026 results, flags second-half pipeline milestonesJul 29Quarterly updatedonidalorsenIonis Pharmaceuticals